clinical trial · NCT07192211
Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG
Rohto Pharmaceutical Co., Ltd.·phase2·recruiting·n = 50
Ischemic Heart DiseaseMesenchymal stem cellPlacebo
brief summary
ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.
started
Apr 28, 2026
primary completion
Sep 30, 2028
completion
Mar 31, 2029
last updated
Jun 9, 2026
detailed description
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study. ADR-002K (Adipose-derived mesenchymal stem cells) is administered to the surface of the heart in patients with ischemic heart disease who undergo CABG. The efficacy and safety of ADR-002K are evaluated until the last patient has completed the 2-year evaluation.
official title
Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo Coronary Artery Bypass Surgery
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol